These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 18444843)

  • 21. [Guillain-Barré syndrome to meningococcal conjugate vaccine: Menveo
    Moukafih B; Lachhab Z; Moutaouakkil Y; Fettah H; Ahizoune A; Tadlaoui Y; Bennana A; Lamsaouri J; Bousliman Y
    Therapie; 2019 Sep; 74(4):495-498. PubMed ID: 30661720
    [No Abstract]   [Full Text] [Related]  

  • 22. Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada.
    De Wals P; Robin E; Fortin E; Thibeault R; Ouakki M; Douville-Fradet M
    Pediatr Infect Dis J; 2008 Nov; 27(11):963-8. PubMed ID: 18845982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006.
    Kinlin LM; Jamieson F; Brown EM; Brown S; Rawte P; Dolman S; Drews SJ; Fisman DN
    Vaccine; 2009 Mar; 27(11):1735-40. PubMed ID: 19186206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Statement on conjugate meningococcal vaccine for serogroups A, C, Y and W135. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2007 May; 33(ACS-3):1-23. PubMed ID: 17520774
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinically diagnosed Guillain-Barre syndrome in Ile-Ife, Nigeria.
    Sunmonu TA; Komolafe MA; Adewuya A; Olugbodi AA
    West Afr J Med; 2008 Jul; 27(3):167-70. PubMed ID: 19256323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2009 Apr; 35(ACS-3):1-40. PubMed ID: 19400026
    [No Abstract]   [Full Text] [Related]  

  • 27. Guillain-Barré syndrome: background incidence rates in The Netherlands.
    van der Maas NA; Kramer MA; Jacobs BC; van Soest EM; Dieleman JP; Kemmeren JM; de Melker HE; Sturkenboom MC
    J Peripher Nerv Syst; 2011 Sep; 16(3):243-9. PubMed ID: 22003939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Guillain-BarrÉ Syndrome After Immunization in Canadian Children (1996-2012).
    Top KA; Desai S; Moore D; Law BJ; Vaudry W; Halperin SA; Bettinger JA;
    Pediatr Infect Dis J; 2015 Dec; 34(12):1411-3. PubMed ID: 26379167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune response to conjugated meningococcal C vaccine in pediatric oncology patients.
    Yu JW; Borkowski A; Danzig L; Reiter S; Kavan P; Mazer BD
    Pediatr Blood Cancer; 2007 Dec; 49(7):918-23. PubMed ID: 17366523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine.
    Sakou II; Tzanakaki G; Tsolia MN; Sioumala M; Barbouni A; Kyprianou M; Papaevangelou V; Tsitsika A; Blackwell CC; Kafetzis D; Kremastinou J
    Vaccine; 2009 Jul; 27(33):4408-11. PubMed ID: 19500554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recognizing Guillain-Barre syndrome in preschool children.
    Roodbol J; de Wit MC; Walgaard C; de Hoog M; Catsman-Berrevoets CE; Jacobs BC
    Neurology; 2011 Mar; 76(9):807-10. PubMed ID: 21357832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of meningococcal vaccines in the United States.
    Bilukha O; Messonnier N; Fischer M
    Pediatr Infect Dis J; 2007 May; 26(5):371-6. PubMed ID: 17468644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pediatric Guillain-Barré Syndrome in a 30-Year Nationwide Cohort.
    Levison LS; Thomsen RW; Markvardsen LK; Christensen DH; Sindrup SH; Andersen H
    Pediatr Neurol; 2020 Jun; 107():57-63. PubMed ID: 32192820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guillain-Barré syndrome incidence in a large United States cohort (2000-2009).
    Shui IM; Rett MD; Weintraub E; Marcy M; Amato AA; Sheikh SI; Ho D; Lee GM; Yih WK;
    Neuroepidemiology; 2012; 39(2):109-15. PubMed ID: 22846726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Guillain-Barre syndrome and SIADH.
    Saifudheen K; Jose J; Gafoor VA; Musthafa M
    Neurology; 2011 Feb; 76(8):701-4. PubMed ID: 21339497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of mortality following a mass immunization campaign with serogroup C meningococcal conjugate vaccine.
    De Wals P
    Vaccine; 2009 Sep; 27(42):5730. PubMed ID: 19651172
    [No Abstract]   [Full Text] [Related]  

  • 37. Guillain-Barre syndrome after vaccination in United States a report from the CDC/FDA Vaccine Adverse Event Reporting System.
    Souayah N; Nasar A; Suri MF; Qureshi AI
    Vaccine; 2007 Jul; 25(29):5253-5. PubMed ID: 17560693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Guillain-Barré Syndrome among recipients of influenza vaccine in 2000 and 2001.
    Burwen DR; Ball R; Bryan WW; Izurieta HS; La Voie L; Gibbs NA; Kliman R; Braun MM
    Am J Prev Med; 2010 Oct; 39(4):296-304. PubMed ID: 20837279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimation of background incidence rates of Guillain-Barré syndrome in Germany - a retrospective cohort study with electronic healthcare data.
    Hense S; Schink T; Kreisel SH; Marcelon L; Simondon F; Tahden M; Garbe E
    Neuroepidemiology; 2014; 43(3-4):244-52. PubMed ID: 25531827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased risk of Guillain-Barré Syndrome following recent herpes zoster: a population-based study across Taiwan.
    Kang JH; Sheu JJ; Lin HC
    Clin Infect Dis; 2010 Sep; 51(5):525-30. PubMed ID: 20642353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.